Proskauer-Led NovoCure Raises $165M In Downgraded IPO

Guided by Proskauer Rose, cancer treatment company NovoCure brought in $165 million with its initial public offering on Friday, pricing below the expected range a day after downgrading the terms, another...

Already a subscriber? Click here to view full article